Kauliv Treatment for Osteoporosis Makes ‘Strides’

The biologics division of Strides Pharma Science, Stelis Biopharma, has said that its new medicine, Kauliv, has been a triumph. The product received favourable responses from the European Medicines Agency (EMA) who suggested approving Kauliv’s marketing approval.

Kauliv helps treat individuals with osteoporosis who have a high chance of experiencing bone breaks or fractures. However, the drug is not universal; applicable users include males, and females once they have passed the menopause.

The existing product leading the market for this type of product (osteoporosis treatments) is Forsteo, which boasts a huge $800 million in revenue. This is equivalent to over 50% total market share, which totals approximately $1.5 trillion. It is widely considered as the best treatment method on the market at the moment.

The manufacturing location where Stelis Biopharma will produce Kauliv is Bangalore, as approved by the regulatory bodies- in the EU and USFDA. Their strategy is to expand their offerings gradually using a Business 2 Business approach.

Twenty nations have already received licences from the firm. Following registrations from country to country, Kauliv will be commercialised, which will build up a series of sales over time.

Strides Pharma Science operates with an “in Africa for Africa” philosophy, aiming to benefit markets funded through charitable donations.

Last week, share prices for the firm increased 1.74% to Rs 318.50.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.